

## 20s Proteasome - Drugs in Development, 2021

<https://marketpublishers.com/r/2FD75D06B938EN.html>

Date: September 2021

Pages: 76

Price: US\$ 3,500.00 (Single User License)

ID: 2FD75D06B938EN

### Abstracts

20s Proteasome - Drugs in Development, 2021

#### SUMMARY

20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report 20s Proteasome - Drugs In Development, 2021, outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic

Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Tuberculosis and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for 20s Proteasome

The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects

The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 20s Proteasome Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

20s Proteasome - Overview

20s Proteasome - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

20s Proteasome - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

20s Proteasome - Companies Involved in Therapeutics Development

Amgen Inc

Bristol-Myers Squibb Co

Centrax International Inc

HuniLife Biotechnology Inc

Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd

Zymergen Inc

20s Proteasome - Drug Profiles

carfilzomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CX-13608 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuL-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

marizomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

**NNU-546 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**RTSV-5 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**TIR-199 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**20s Proteasome - Dormant Products****20s Proteasome - Product Development Milestones****Featured News & Press Releases**

Jul 09, 2021: BeiGene announces the approval in China of KYPROLIS (Carfilzomib) for injection for adult patients with relapsed or refractory multiple myeloma

Mar 22, 2021: Triple therapy recommended by NICE for patients with multiple myeloma

Nov 30, 2020: Amgen announces new data on KYPROLIS At ASH 2020

Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis

Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combination regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens

May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020

May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer

Dec 11, 2019: Amgen reports positive data in multiple myeloma study

Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019

Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival

Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019

Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events

Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma

Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indications, 2021  
Number of Products under Development by Indications, 2021 (Contd..1)  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Amgen Inc, 2021  
Pipeline by Bristol-Myers Squibb Co, 2021  
Pipeline by Centrax International Inc, 2021  
Pipeline by HuniLife Biotechnology Inc, 2021  
Pipeline by Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd, 2021  
Pipeline by Zymergen Inc, 2021  
Dormant Products, 2021  
Dormant Products, 2021 (Contd..1)  
Dormant Products, 2021 (Contd..2)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021



## I would like to order

Product name: 20s Proteasome - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/2FD75D06B938EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2FD75D06B938EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970